Treats pain and inflammation associated with cataract surgery. Sold as Nevanac, Ilevro. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Nepafenac (sold as Nevanac, Ilevro), first approved Aug 19, 2005, with 0 new uses approved and 0 published complete response letters.
| Ilevro | Part D | $10.3M | -30% | 13,521 |
| Nevanac | Part D | $1.5M | -16% | 1,251 |
| A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum StenosisEpiphora, Punctal Stenosis · Instituto de Oftalmología Fundación Conde de Valenciana | Phase 4 | Active, not recruiting | Jan 28, 2026 |
| The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)Post Cataract Surgery · Research Insight LLC | Phase 4 | Not yet recruiting | Dec 11, 2025 |
| Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract SurgeryMacular Oedema, Cataract Surgery · Nemocnice Kolín | Not applicable | Recruiting | Sep 17, 2025 |
| Aug 19, 2005 | NevanacNDA 21862 · New molecular entity | Harrow Eye | 5 | Marketed |
| Oct 16, 2012 | IlevroNDA 203491 · New formulation or manufacturer | Harrow Eye | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
